RAPT Therapeutics 주식 주식분석 | 주식가격 | 뉴스 | RAPT | US75382E1091 | A2PNYQ

날짜	RAPT Therapeutics 주식 가격
	1.12 undefined
	1.10 undefined
	1.11 undefined
	1.28 undefined
	1.74 undefined
	1.74 undefined
	1.75 undefined
	2.89 undefined
	3.10 undefined
	2.72 undefined
	2.45 undefined
	2.27 undefined
	2.23 undefined
	2.12 undefined
	2.20 undefined
	2.00 undefined
	1.93 undefined
	1.89 undefined
	1.77 undefined
	1.72 undefined
	1.79 undefined
	1.65 undefined

날짜	RAPT Therapeutics 매출	RAPT Therapeutics EBIT	RAPT Therapeutics 이익
2029e	303.01 백만 undefined	0 undefined	27.77 백만 undefined
2028e	155.58 백만 undefined	-358.02 백만 undefined	-76.71 백만 undefined
2027e	88.23 백만 undefined	-302.94 백만 undefined	-132.78 백만 undefined
2026e	12.57 백만 undefined	-148.41 백만 undefined	-76.54 백만 undefined
2025e	0 undefined	-102.96 백만 undefined	-67.35 백만 undefined
2024e	0 undefined	-111.63 백만 undefined	-90.42 백만 undefined
2023	0 undefined	-127.06 백만 undefined	-116.8 백만 undefined
2022	1.53 백만 undefined	-85.8 백만 undefined	-83.84 백만 undefined
2021	3.81 백만 undefined	-69.21 백만 undefined	-69.2 백만 undefined
2020	5.04 백만 undefined	-53.21 백만 undefined	-52.89 백만 undefined
2019	0 undefined	-43.63 백만 undefined	-43 백만 undefined
2018	0 undefined	-36.95 백만 undefined	-36.15 백만 undefined
2017	0 undefined	-29.33 백만 undefined	-29.12 백만 undefined

	매출	EBIT	이익
2017	0 USD	-29.33 백만 USD	-29.12 백만 USD
2018	0 USD	-36.95 백만 USD	-36.15 백만 USD
2019	0 USD	-43.63 백만 USD	-43 백만 USD
2020	5.04 백만 USD	-53.21 백만 USD	-52.89 백만 USD
2021	3.81 백만 USD	-69.21 백만 USD	-69.2 백만 USD
2022	1.53 백만 USD	-85.8 백만 USD	-83.84 백만 USD
2023	0 USD	-127.06 백만 USD	-116.8 백만 USD
2024e	0 USD	-111.63 백만 USD	-90.42 백만 USD
2025e	0 USD	-102.96 백만 USD	-67.35 백만 USD
2026e	12.57 백만 USD	-148.41 백만 USD	-76.54 백만 USD
2027e	88.23 백만 USD	-302.94 백만 USD	-132.78 백만 USD
2028e	155.58 백만 USD	-358.02 백만 USD	-76.71 백만 USD
2029e	303.01 백만 USD	0 USD	27.77 백만 USD

2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e
0	0	0	5	3	1	0	0	0	12	88	155	303
-	-	-	-	-40.00	-66.67	-	-	-	-	633.33	76.14	95.48
-	-	-	-	-	-	-	-	-	-	-	-	-
0	0	0	0	0	0	0	0	0	0	0	0	0
-29	-36	-43	-52	-69	-83	-116	-90	-67	-76	-132	-76	27
-	24.14	19.44	20.93	32.69	20.29	39.76	-22.41	-25.56	13.43	73.68	-42.42	-135.53
22.75	22.75	22.75	24.13	27.39	32.54	38.34	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-

2017	2018	2019	2020	2021	2022	2023

47.5	63.8	77.4	111.5	189.7	249.1	158.86
0	0	0	0	0	0	0
0	0	0	0	0	0	0
0	0	0	0	0	0	0
0.7	1.3	3.1	4.1	3.3	3.6	2.92
48.2	65.1	80.5	115.6	193	252.7	161.78
1.9	4.2	3.7	3	2.7	9.5	7.68
0	0	0	0	0	0	0
0	0	0	0	0	0	0
0	0	0	0	0	0	0
0	0	0	0	0	0	0
0.2	0.4	0.4	0.4	2.9	4	3.87
2.1	4.6	4.1	3.4	5.6	13.5	11.55
50.3	69.7	84.6	119	198.6	266.2	173.33

108.6	161.1	0	0	0	0	0
21	22.4	235	319.2	470.6	613.1	631.61
-82.8	-119	-162	-214.8	-284	-367.9	-484.68
-600	-600	0	-200	-200	0	103
0	0	0	0	0	0	0
46.2	63.9	73	104.2	186.4	245.2	147.04
1.1	1.8	1.1	2.4	2	3.4	5.18
1.5	2.5	3.6	4.9	6.3	10.8	16.55
0.7	0.4	4.5	4.4	1.3	0	0.11
0	0	0	0	0	0	0
0	0	0	0	0	0	0
3.3	4.7	9.2	11.7	9.6	14.2	21.84
0	0	0	0	0	0	0
0	0	0	0	0	0	0
0.9	1	2.2	3	2.7	6.8	4.46
0.9	1	2.2	3	2.7	6.8	4.46
4.2	5.7	11.4	14.7	12.3	21	26.29
50.4	69.6	84.4	118.9	198.7	266.2	173.33

2017	2018	2019	2020	2021	2022	2023
-29	-36	-43	-52	-69	-83	-116
1,000	1,000	1,000	1,000	1,000	1,000	1,000
0	0	0	0	0	0	0
0	0	4	2	-4	-1	5
1	2	4	17	21	24	30
0	0	0	0	0	0	0
0	0	0	0	0	0	0
-27	-32	-35	-40	-61	-70	-97
-1	-3	0	0	0	0	-1
-1	-3	0	-87	-81	-45	104
0	0	0	-87	-80	-44	105
0	0	0	0	0	0	0
0	0	0	0	0	0	0
30	52	49	75	141	131	1
30	52	49	75	141	131	1
-	-	-	-	-	-	-
0	0	0	0	0	0	0
1	16	13	-52	0	14	8
-28.24	-36.45	-36.36	-40.89	-61.79	-71.62	-98.17
0	0	0	0	0	0	0

RAPT Therapeutics 브루토마진	RAPT Therapeutics EBIT-마진	RAPT Therapeutics 이익 마진
2029e	0 %	9.16 %
2028e	-230.12 %	-49.31 %
2027e	-343.35 %	-150.49 %
2026e	-1,180.49 %	-608.78 %
2025e	0 %	0 %
2024e	0 %	0 %
2023	0 %	0 %
2022	-5,607.84 %	-5,479.74 %
2021	-1,816.54 %	-1,816.27 %
2020	-1,055.75 %	-1,049.4 %
2019	0 %	0 %
2018	0 %	0 %
2017	0 %	0 %

	EBIT-마진	이익 마진
2017	0 %	0 %
2018	0 %	0 %
2019	0 %	0 %
2020	-1,055.75 %	-1,049.4 %
2021	-1,816.54 %	-1,816.27 %
2022	-5,607.84 %	-5,479.74 %
2023	0 %	0 %
2024e	0 %	0 %
2025e	0 %	0 %
2026e	-1,180.49 %	-608.78 %
2027e	-343.35 %	-150.49 %
2028e	-230.12 %	-49.31 %
2029e	0 %	9.16 %

날짜	RAPT Therapeutics 주당 매출	RAPT Therapeutics EBIT 당 주식	RAPT Therapeutics 주당 이익
2029e	8.68 undefined	0 undefined	0.8 undefined
2028e	4.46 undefined	0 undefined	-2.2 undefined
2027e	2.53 undefined	0 undefined	-3.8 undefined
2026e	0.36 undefined	0 undefined	-2.19 undefined
2025e	0 undefined	0 undefined	-1.93 undefined
2024e	0 undefined	0 undefined	-2.59 undefined
2023	0 undefined	-3.31 undefined	-3.05 undefined
2022	0.05 undefined	-2.64 undefined	-2.58 undefined
2021	0.14 undefined	-2.53 undefined	-2.53 undefined
2020	0.21 undefined	-2.21 undefined	-2.19 undefined
2019	0 undefined	-1.92 undefined	-1.89 undefined
2018	0 undefined	-1.62 undefined	-1.59 undefined
2017	0 undefined	-1.29 undefined	-1.28 undefined

	주당 매출	EBIT 당 주식	주당 이익
2017	0 USD	-1.29 USD	-1.28 USD
2018	0 USD	-1.62 USD	-1.59 USD
2019	0 USD	-1.92 USD	-1.89 USD
2020	0.21 USD	-2.21 USD	-2.19 USD
2021	0.14 USD	-2.53 USD	-2.53 USD
2022	0.05 USD	-2.64 USD	-2.58 USD
2023	0 USD	-3.31 USD	-3.05 USD
2024e	0 USD	0 USD	-2.59 USD
2025e	0 USD	0 USD	-1.93 USD
2026e	0.36 USD	0 USD	-2.19 USD
2027e	2.53 USD	0 USD	-3.8 USD
2028e	4.46 USD	0 USD	-2.2 USD
2029e	8.68 USD	0 USD	0.8 USD

	주식 수량
2017	22.75 백만 Aktien
2018	22.75 백만 Aktien
2019	22.75 백만 Aktien
2020	24.13 백만 Aktien
2021	27.39 백만 Aktien
2022	32.54 백만 Aktien
2023	38.34 백만 Aktien
2024e	38.34 백만 Aktien
2025e	38.34 백만 Aktien
2026e	38.34 백만 Aktien
2027e	38.34 백만 Aktien
2028e	38.34 백만 Aktien
2029e	38.34 백만 Aktien

EPS-예상치	EPS-실제	보고 분기
-0.73	-0.71 (3.32 %)	2024 Q2
-0.82	-0.79 (4.17 %)	2024 Q1
-0.88	-0.8 (8.68 %)	2023 Q4
-0.77	-0.82 (-6.73 %)	2023 Q3
-0.8	-0.66 (17.22 %)	2023 Q2
-0.69	-0.76 (-9.57 %)	2023 Q1
-0.67	-0.64 (4.06 %)	2022 Q4
-0.68	-0.63 (7.81 %)	2022 Q3
-0.77	-0.62 (18.95 %)	2022 Q2
-0.69	-0.69 (0.33 %)	2022 Q1
-0.67	-0.61 (9 %)	2021 Q4
-0.64	-0.63 (0.83 %)	2021 Q3
-0.68	-0.63 (7.54 %)	2021 Q2
-0.64	-0.66 (-3.69 %)	2021 Q1
-0.61	-0.52 (14.08 %)	2020 Q4
-0.59	-0.6 (-2.3 %)	2020 Q3
-0.59	-0.51 (13.29 %)	2020 Q2
-0.44	-0.56 (-27.68 %)	2020 Q1
-0.71	-0.82 (-15.67 %)	2019 Q4
-0.65	-12.41 (-1,801.04 %)	2019 Q3

%-지분	이름	주식	변경
15.00077 %	Fidelity Management & Research Company LLC	5,235,268	15,866
8.90621 %	The Vanguard Group, Inc.	3,108,268	621,163
7.68086 %	The Column Group LP	2,680,621	0
6.28853 %	BlackRock Institutional Trust Company, N.A.	2,194,697	-34,017
4.94269 %	Kingdon Capital Management, L.L.C.	1,725,000	225,000
3.75560 %	Two Sigma Investments, LP	1,310,705	542,602
2.93427 %	Millennium Management LLC	1,024,061	781,906
2.90620 %	Morgan Stanley & Co. LLC	1,014,265	-473,674
2.67204 %	DWS Investments UK Limited	932,541	643,955
2.60004 %	D. E. Shaw & Co., L.P.	907,413	637,272
2.28103 %	Federated MDTA LLC	796,080	520,368
2.02665 %	Point72 Asset Management, L.P.	707,300	706,900
1.96193 %	Geode Capital Management, L.L.C.	684,713	5,497
1.92489 %	State Street Global Advisors (US)	671,785	12,383
1.88510 %	Euclidean Capital, L.L.C.	657,899	0
1.54805 %	Alphabet, Inc.	540,270	0
1.53777 %	Redmile Group, LLC	536,682	-125,716
1.43266 %	Ardsley Advisory Partners LP	500,000	97,500
1.42335 %	Cormorant Asset Management, LP	496,750	0
1.41151 %	Wong (Brian Russell)	492,618	7,148
1.33863 %	Acadian Asset Management LLC	467,182	456,275
0.95093 %	Dimensional Fund Advisors, L.P.	331,876	-224,928
0.90258 %	Sio Capital Management, LLC	315,000	0
0.84596 %	Cubist Systematic Strategies, LLC	295,241	263,372
0.83668 %	Octagon Capital Advisors LP	292,000	0
0.70023 %	Northern Trust Investments, Inc.	244,382	-19,683
0.62022 %	Goldman Sachs Asset Management, L.P.	216,457	199,495
0.59638 %	Charles Schwab Investment Management, Inc.	208,138	-27,518
0.58424 %	Renaissance Technologies LLC	203,900	105,900
0.57597 %	Jane Street Capital, L.L.C.	201,013	80,248
0.57174 %	T. Rowe Price Associates, Inc.	199,538	-1,819,667
0.47559 %	Woodline Partners LP	165,981	-155,632
0.45081 %	Goldman Sachs & Company, Inc.	157,331	-11,930
0.44778 %	Parametric Portfolio Associates LLC	156,275	152,570
0.44305 %	Ikarian Capital LLC	154,625	0
0.41364 %	Trexquant Investment LP	144,362	-13,280
0.38583 %	BlackRock Financial Management, Inc.	134,656	35,081
0.33179 %	Walleye Capital LLC	115,794	38,381
0.31447 %	Caption Management, LLC	109,750	0
0.30944 %	Squarepoint Capital LLP	107,994	107,994
0.28739 %	Norges Bank Investment Management (NBIM)	100,300	0
0.28024 %	PDT Partners, LLC	97,805	97,805
0.27141 %	Rieflin (William J L)	94,722	0
0.27129 %	Graham Capital Management, L.P.	94,680	71,370
0.25976 %	BofA Global Research (US)	90,656	-18,599
0.25523 %	Exchange Traded Concepts, LLC	89,076	63,235
0.25322 %	AQR Capital Management, LLC	88,373	88,373
0.25256 %	BlackRock Investment Management, LLC	88,145	12,250
0.24237 %	Los Angeles Capital Management LLC	84,586	33,692
0.21979 %	Nuveen LLC	76,707	-28,300
0.21490 %	Affinity Asset Advisors LLC	75,000	75,000
0.21027 %	Trustees of Columbia University in the City of New York	73,383	0
0.20912 %	BNY Mellon Asset Management	72,982	3,380
0.15996 %	Verition Fund Management LLC	55,825	55,825
0.15471 %	Thrivent Asset Management, LLC	53,993	53,993
0.15371 %	PGIM Quantitative Solutions LLC	53,645	43,445
0.14530 %	AllianceBernstein L.P.	50,710	19,810
0.14034 %	LSV Asset Management	48,977	20,805
0.13733 %	Hennion & Walsh Asset Management, Inc.	47,927	-598
0.13605 %	Algert Global LLC	47,483	-6,405
0.13408 %	SEI Investments Management Corporation	46,794	21,100
0.13327 %	Rhumbline Advisers Ltd. Partnership	46,512	2,988
0.13080 %	Jasper Ridge Partners, L.P.	45,650	0
0.12908 %	Boothbay Fund Management, LLC	45,050	0
0.11203 %	Mellon Investments Corporation	39,100	16,675
0.11146 %	T. Rowe Price Japan, Inc.	38,900	20,400
0.10503 %	GSA Capital Partners LLP	36,654	36,654
0.10166 %	XTX Markets LLC	35,480	35,480
0.08191 %	UBS Financial Services, Inc.	28,588	-26,979
0.07947 %	Northern Trust Global Investments	27,736	-1,125
0.07880 %	Robbins (Wendye)	27,500	0
0.07257 %	Goldman Sachs Asset Management International	25,327	4,257
0.07256 %	Manulife Investment Management (North America) Limited	25,325	-10,864
0.06461 %	Brockstedt (Dirk G)	22,548	-898
0.06259 %	Dimensional Fund Advisors, Ltd.	21,845	0
0.05731 %	LMR Partners LLP	20,000	0
0.05706 %	State Street Global Advisors Ireland Limited	19,914	-72
0.05330 %	BlackRock Advisors (UK) Limited	18,600	406
0.05330 %	BlackRock Asset Management Ireland Limited	18,600	-20,814
0.04992 %	Stifel, Nicolaus & Company, Incorporated	17,421	17,421
0.04624 %	Corebridge Financial Inc	16,139	16,139
0.04605 %	Pale Fire Capital SE	16,070	16,070
0.04510 %	Ho William	15,740	3,648
0.04494 %	Mirae Asset Global Investments (USA) LLC	15,685	3,033
0.04389 %	Citi Investment Research (US)	15,316	10,056
0.04171 %	SunAmerica Asset Management, LLC	14,556	-125
0.04129 %	Quinn Opportunity Partners LLC	14,409	0
0.04008 %	Assenagon Asset Management S.A.	13,989	-69
0.03777 %	Wells Fargo Bank, N.A.	13,180	3,956
0.03663 %	JPMorgan Private Bank (United States)	12,785	1,205
0.03513 %	TD Asset Management Inc.	12,262	0
0.03362 %	Young (Rodney K B)	11,732	1,648
0.03309 %	New York State Common Retirement Fund	11,549	0
0.03190 %	Susquehanna International Group, LLP	11,134	-50,840
0.03152 %	Abaris Investment Management AG	11,000	3,000
0.03123 %	Prelude Capital Management, LLC	10,900	10,900
0.03083 %	Tower Research Capital LLC	10,758	6,724
0.03040 %	SG Americas Securities, L.L.C.	10,608	10,608
0.03022 %	Cerity Partners LLC	10,546	10,546
0.03017 %	Invesco Advisers, Inc.	10,528	-1,570

이름	관계	이주간 상관관계	원월 상관관계	삼개월 상관계수	여섯달 상관관계	일년간 상관관계	이년 상관관계
Merck & Co	공급업체고객	-0,24	-0,05	-0,71	-0,63	-0,53	-0,06

What values and corporate philosophy does RAPT Therapeutics represent?

Rapt Therapeutics Inc is committed to delivering innovative solutions in the field of oncology. Their corporate philosophy revolves around advancing the understanding of the immune system and developing targeted therapies to improve patient outcomes. Rapt Therapeutics Inc values scientific excellence, collaboration, and a patient-centric approach. With a focus on precision medicine, they aim to harness the potential of immunology to treat cancers effectively. Through their dedication to research and development, Rapt Therapeutics Inc strives to make a difference in the lives of cancer patients by providing transformative treatment options.

In which countries and regions is RAPT Therapeutics primarily present?

Rapt Therapeutics Inc is primarily present in the United States.

What significant milestones has the company RAPT Therapeutics achieved?

Some significant milestones achieved by Rapt Therapeutics Inc include the completion of successful clinical trials for their lead drug candidate, FLX475, which has shown promising results in the treatment of multiple cancers. Additionally, Rapt Therapeutics Inc received the Orphan Drug Designation from the FDA for FLX475, highlighting the drug's potential in addressing rare diseases. The company has also established strategic collaborations with renowned research institutions and pharmaceutical companies to further advance their pipeline of innovative therapeutics. These achievements demonstrate Rapt Therapeutics Inc's dedication to developing novel treatments and their commitment to improving patients' lives.

What is the history and background of the company RAPT Therapeutics?

Rapt Therapeutics Inc is a biopharmaceutical company based in the United States. The company focuses on developing therapies to modulate the immune system and target critical immune checkpoints for the treatment of cancer. Rapt Therapeutics Inc was founded in 2015 and has since been dedicated to advancing their innovative drug pipeline. With a mission to improve the lives of patients, Rapt Therapeutics Inc combines cutting-edge research and scientific expertise to develop novel treatment options for a range of cancers.

Who are the main competitors of RAPT Therapeutics in the market?

The main competitors of Rapt Therapeutics Inc in the market include companies such as Merck & Co., Inc., Bristol-Myers Squibb Company, and Genentech, Inc. These companies operate in the pharmaceutical industry and are engaged in developing and marketing therapies and treatments for various diseases and medical conditions. Rapt Therapeutics Inc faces competition in terms of research and development, as well as commercialization of innovative therapies.

In which industries is RAPT Therapeutics primarily active?

Rapt Therapeutics Inc is primarily active in the biotechnology industry.

What is the business model of RAPT Therapeutics?

The business model of Rapt Therapeutics Inc. focuses on developing and commercializing transformative small molecule drugs for patients with unmet medical needs. The company focuses on the discovery and development of oral small molecule therapies that target critical signaling pathways involved in various diseases. Rapt Therapeutics Inc. aims to leverage its expertise in immunology and oncology to identify and develop potential therapeutic candidates. Through rigorous research and development, the company aims to bring innovative drugs to the market, ultimately improving patient outcomes and addressing significant unmet medical needs.

RAPT Therapeutics 2024의 P/E 비율은 얼마입니까?

RAPT Therapeutics의 P/E 비율은 -0.47입니다.

RAPT Therapeutics 2024의 KUV는 얼마입니까?

RAPT Therapeutics의 P/S 비율은 0입니다.

RAPT Therapeutics의 AlleAktien 품질 점수는 얼마인가요?

RAPT Therapeutics에 대한 AlleAktien 품질 점수는 2/10입니다.

RAPT Therapeutics 2024의 매출은 얼마인가요?

RAPT Therapeutics에 대한 현재 매출은 계산할 수 없습니다.

RAPT Therapeutics 2024의 이익은 얼마인가요?

예상되는 RAPT Therapeutics 이익은 -90.42 백만 USD입니다.

RAPT Therapeutics은 무엇을 하나요?

Rapt Therapeutics Inc is a biopharmaceutical company based in San Francisco, California, focused on the development and commercialization of therapeutics for the treatment of cancer and inflammatory diseases. The company was founded in 2015. Rapt Therapeutics' business model is based on an innovative platform for identifying target molecules and researching and developing small molecules for the targeted treatment of cancer and inflammation. The company utilizes the body's own immune cells to fight tumors. Rapt Therapeutics has developed several products in recent years, including FLX475 for the treatment of cancer and inflammatory diseases. FLX475 is an orally administered drug that inhibits the activation of T cells, resulting in an anti-inflammatory effect. Rapt Therapeutics currently has four cancer drugs in the pipeline, including IL-4Ra antagonists for the treatment of nervous system cancer. Another aspect of the company's business is collaboration with other biopharmaceutical companies to develop innovative therapeutics based on the Rapt platform technology. Rapt Therapeutics works with leading companies in the industry such as Merck, Pfizer, and Genentech. The Rapt platform technology is unique and facilitates the search for suitable target molecules and potential drugs. A key part of Rapt Therapeutics' business model is also collaboration with scientific partners, primarily academic research institutions. The research and development of innovative cancer therapies requires close collaboration between the industry and the academic research community. Rapt Therapeutics specializes in collaborating with leading academic institutions to accelerate research in innovative ways. To ensure that the company can always offer its customers the latest research findings and technologies, Rapt Therapeutics also invests in research and development in other areas such as genomics, biology, and immunology. In summary, Rapt Therapeutics' business model is to develop and strategically use innovative chemicals to effectively treat cancer and inflammatory diseases. The company's platform technology allows for fast and targeted search for the best target molecules and potential drugs. Collaboration with other companies and academic institutions plays an important role in accelerating research findings in innovative ways.

RAPT Therapeutics 배당금은 얼마입니까?

RAPT Therapeutics은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

RAPT Therapeutics이 얼마나 자주 배당을 지급하나요?

RAPT Therapeutics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

RAPT Therapeutics ISIN이 무엇입니까?

RAPT Therapeutics의 ISIN은 US75382E1091입니다.

RAPT Therapeutics WKN은 무엇인가요?

RAPT Therapeutics의 WKN은 A2PNYQ입니다.

RAPT Therapeutics 티커는 무엇인가요?

RAPT Therapeutics의 티커는 RAPT입니다.

RAPT Therapeutics이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 RAPT Therapeutics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 RAPT Therapeutics은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

RAPT Therapeutics의 배당 수익률은 얼마입니까?

RAPT Therapeutics의 현재 배당 수익률은 입니다.

RAPT Therapeutics의 배당금은 언제 지급되나요?

RAPT Therapeutics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

RAPT Therapeutics의 배당금은 얼마나 안전한가요?

RAPT Therapeutics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

RAPT Therapeutics의 배당금은 얼마입니까?

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

RAPT Therapeutics이(가) 속해 있는 섹터는 어디인가요?

RAPT Therapeutics은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von RAPT Therapeutics kaufen, um die vorherige Dividende zu erhalten?

RAPT Therapeutics의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

RAPT Therapeutics의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

RAPT Therapeutics의 2023년도 배당금은 얼마였습니까?

2023년에 RAPT Therapeutics는 0 USD를 배당금으로 지급했습니다.

RAPT Therapeutics는 어떤 화폐로 배당금을 지급하나요?

RAPT Therapeutics의 배당금은 USD에 지급됩니다.

Scope 1 - 직접 방출
스코프 2 - 구매한 에너지로부터의 간접적인 배출
Scope 3 - 가치 창출 체인 내의 간접 배출
총 CO₂ 배출량
CO₂ 감소 전략
석탄 에너지
원자력
동물 실험
펠츠 & 레더
살충제
팜 오일
담배
유전자 변형 생물체
기후 개념
지속 가능한 임업
재활용 규정
환경 친화적인 포장
위험물질
연료 소비량과 효율성
물 사용량 및 효율성

여성 직원 비율
관리 직위에서의 여성 비율
아시아 직원 비율
아시아 경영진 비율
히스패닉/라티노 직원 비율
히스패닉/라티노 관리 부문 지분
흑인 직원 비율
블랙 매니지먼트 지분
흰색 종업원의 비율
화이트 매니지먼트 지분
성인 콘텐츠
알코올
무기
총기
도박
군사 계약
인권 개념
개인정보 보호 정책
작업 및 건강 보호
카톨릭

환경 보고
이해관계자 참여
콜백 정책
카르텔법

증권거래소	RAPT Therapeutics 티커
뒤셀도르프	0RA.DU
프랑크푸르트	0RA.F
뮌헨	0RA.MU
NASDAQ	RAPT

RAPT Therapeutics 티커	RAPT Therapeutics FIGI
RAPT:US	BBG00PGK50M2
RAPT:UA	BBG00PNNDZR7
RAPT:UC	BBG00PNNDZS6
RAPT:UN	BBG00PNNDZV2
RAPT:UP	BBG00PNNDZW1
RAPT:UQ	BBG00PNNDZX0
RAPT:UB	BBG00PNNDZY9
RAPT:UM	BBG00PNNF001
RAPT:UX	BBG00PNNF010
RAPT:UD	BBG00PNNF065
RAPT:UF	BBG00PNNF092
RAPT:VY	BBG00PNNF0B9
RAPT:VJ	BBG00PNNF0C8
RAPT:VK	BBG00PNNF0D7
RAPT:VF	BBG00PNNF0F5
0RA:GR	BBG00PZCLM07
0RA:GF	BBG00PZCLM16
0RA:GD	BBG00PZCLM25
0RA:GS	BBG00PZCLM43
0RA:GM	BBG00PZCLM52
0RA:GB	BBG00PZCLM61
0RA:GZ	BBG00PZCVT56
RAPTEUR:XS	BBG00PZDPRS0
RAPTEUR:XH	BBG00PZDPRW5
RAPTEUR:XF	BBG00PZDPRY3
RAPTEUR:XE	BBG00PZDPS08
RAPTEUR:XJ	BBG00PZDPS17
RAPTEUR:XL	BBG00PZDPS26
RAPTEUR:XG	BBG00PZDPS35
RAPTEUR:XO	BBG00PZDPS44
RAPTEUR:XA	BBG00PZDPS80
RAPTEUR:XT	BBG00PZDPSB6
RAPTEUR:XW	BBG00PZDPSC5
RAPTEUR:XU	BBG00PZDPSD4
RAPTEUR:XV	BBG00PZDPSF2
RAPTEUR:XM	BBG00PZDPSG1
RAPTEUR:EU	BBG00PZDPSN3
0RA:TH	BBG00QRX8KD3
0RA:QT	BBG00QS35J44
RAPTEUR:EP	BBG00QS4Y9H8
RAPTEUR:EZ	BBG00QS4Y9K4
RAPTUSD:EP	BBG00R0D9V49
RAPTUSD:EZ	BBG00R0D9V67
RAPTUSD:XS	BBG00R0D9V76
RAPTUSD:X2	BBG00R0D9V85
RAPTUSD:XH	BBG00R0D9VB1
RAPTUSD:XF	BBG00R0D9VD9
RAPTUSD:XE	BBG00R0D9VG6
RAPTUSD:XJ	BBG00R0D9VH5
RAPTUSD:XL	BBG00R0D9VJ3
RAPTUSD:XG	BBG00R0D9VK1
RAPTUSD:XO	BBG00R0D9VL0
RAPTUSD:XA	BBG00R0D9VQ5
RAPTUSD:E1	BBG00R0D9VR4
RAPTUSD:XT	BBG00R0D9VS3
RAPTUSD:XW	BBG00R0D9VT2
RAPTUSD:XU	BBG00R0D9VV9
RAPTUSD:XV	BBG00R0D9VX7
RAPTUSD:XM	BBG00R0D9VY6
RAPTUSD:XQ	BBG00R0D9VZ5
RAPTUSD:XX	BBG00R0D9W01
RAPTUSD:XZ	BBG00R0D9W10
RAPTUSD:X1	BBG00R0D9W38
RAPTUSD:EU	BBG00R0D9W56
RAPT:VG	BBG00X1PHRK0
RAPT:VP	BBG00X1SY4Y1
RAPTGBP:XS	BBG00YMVB8T1
RAPTGBP:X2	BBG00YMVB8V8
RAPTGBP:XH	BBG00YMVB8X6
RAPTGBP:XF	BBG00YMVB8Z4
RAPTGBP:XE	BBG00YMVB919
RAPTGBP:XJ	BBG00YMVB928
RAPTGBP:XL	BBG00YMVB937
RAPTGBP:XG	BBG00YMVB946
RAPTGBP:XO	BBG00YMVB955
RAPTGBP:XA	BBG00YMVB991
RAPTGBP:E1	BBG00YMVB9B8
RAPTGBP:XT	BBG00YMVB9C7
RAPTGBP:XW	BBG00YMVB9D6
RAPTGBP:XU	BBG00YMVB9F4
RAPTGBP:XV	BBG00YMVB9H2
RAPTGBP:XM	BBG00YMVB9J0
RAPTGBP:XQ	BBG00YMVB9K8
RAPTGBP:XX	BBG00YMVB9L7
RAPTGBP:XZ	BBG00YMVB9M6
RAPTGBP:X1	BBG00YMVB9P3
RAPTGBP:EU	BBG00YMVB9T9
0RA:LA	BBG018H9S9K1
0RA:LU	BBG018J3FV90

한 눈에 저평가된 주식을 인식하세요

가격

가격

티커RAPT

ISINUS75382E1091

WKNA2PNYQ

RAPT Therapeutics 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

RAPT Therapeutics 주가 이력

RAPT Therapeutics 주식 매출, EBIT, 이익 US75382E1091 · A2PNYQ

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

RAPT Therapeutics 매출, 이익 및 EBIT 역사

RAPT Therapeutics 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

RAPT Therapeutics 주식 마진 US75382E1091 · A2PNYQ

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

RAPT Therapeutics 마진 역사

RAPT Therapeutics 주식 매출, EBIT, 주당 순이익 US75382E1091 · A2PNYQ

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

RAPT Therapeutics 매출, 이익 및 EBIT 주당 역사

RAPT Therapeutics 주식 및 주식 분석

한눈에 과소평가된 주식을 인식하세요.

RAPT Therapeutics Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

RAPT Therapeutics 역사적인 P/E, EBIT 및 P/S에 따른 평가

한눈에 과소평가된 주식을 인식하세요.

RAPT Therapeutics 주식 수량 US75382E1091 · A2PNYQ

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

한눈에 과소평가된 주식을 인식하세요.

RAPT Therapeutics 수익 예상

RAPT Therapeutics 수익 놀라움

Eulerpool ESG Scorecard© RAPT Therapeutics 주식을 위해

Eulerpool World ESG Rating (EESG©)

51/ 100

🌱 Environment

👫 Social

🏛️ Governance

환경

소셜 (사회적)

티커
RAPT

ISIN
US75382E1091

WKN
A2PNYQ